Zhejiang DiAn Diagnostics Co (300244) fair value: what the stock is really worth
We calculate from audited financials what Zhejiang DiAn Diagnostics Co is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Watch Zhejiang DiAn Diagnostics Co for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for free
Dian Diagnostics Group Co.,Ltd. provides integrated medical diagnostics solutions with independent diagnostic services in China.
Show more
Dian Diagnostics Group Co.,Ltd. provides integrated medical diagnostics solutions with independent diagnostic services in China. The company offers laboratory supplies and kits; AI-assisted digital pathology diagnosis solutions, such as nucleic acid extraction and purification system, automatic liquid-based cytology slide preparation and staining system, digital pathology slide scanner, automated pathology slide staining system, genotyping DNA test kit, human papillomavirus nucleic acid detection kit, PCR system and detection system, and virus collection and preservation system; and multi-omics platform services. It also provides DP-TOF nucleic acid mass spectrometry solutions, including mass spectroscopy system, automatic sample processing system, respiratory pathogens multiple detection kit, and nucleic acid sample pretreatment reagent kit; and forensic drug testing products comprises diangio, hair drug trace tester and detector, and saliva and urine drug testing product series. In addition, the company offers supply chain optimization, information management, cold chain logistics, intelligent warehousing, sample library management, scientific research services, etc., as well as solutions for laboratory quality. Further, it is involved in the research and development of diagnostic products; and vitro diagnostic reagents, as well as forensic identification, health management, and other fields. The company was formerly known as Zhejiang DIAN Diagnostics Co., Ltd. and changed its name to Dian Diagnostics Group Co.,Ltd. in November 2017. Dian Diagnostics Group Co.,Ltd. was founded in 1996 and is based in Hangzhou, China.
Stock analysis
Zhejiang DiAn Diagnostics Co (300244) currently trades at ¥16.99, while our model-based Fair Value estimate is ¥12.74, implying the stock looks roughly 33.4% overvalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of ¥37.87 per share, and 12 of the 24 models we run sit above the ¥16.99 price.
Bear case: the Earnings-Based group reads lowest at ¥1.50, and 12 of the 24 models stay below the price. Evidence for this calculation is low.
Quality & growth
The Quality Score stands at 61/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Zhejiang DiAn Diagnostics Co reported revenue of 10.1B CNY in FY2025 versus 13.1B CNY in FY2021, a compound −6.3%/yr. Reported net income was 44.1M CNY in FY2025, compounding −55.9%/yr from FY2021.
Key figures
Market cap 11.6B CNY (≈ $1.7B) · P/E ratio 80.9 · P/S ratio 0.35 · EPS (TTM) ¥0.2100 · Dividend yield 2.1% · Net margin 0.4% · Return on equity 2.8% · Return on assets (EBIT) 7.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (medium confidence).
What moves the price
The share trades about 49% below its 52-week high and 26% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 1% fair-value upside, at −25%, 300244 screens richer than that median.
Fair Value models
Bear ¥12.74Fair Value ¥12.74Bull ¥12.74
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−17.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−20.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.1%
Revenue growth 17 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+26.8%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−42.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year−44.1%
Dividend (yield on the price)2.1%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−44% vs −15%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.12% → 7%
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−10.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+3.0%
Yearly sales growth analysts expect, extended to five years.
Compare Zhejiang DiAn Diagnostics Co with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 140 stocks
Beats the industry median on 9/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score61 · Above median
Fair Value upside−81% · Bottom 25%
Profitability
Return on equity (TTM)3% · Above median
Return on assets3% · Above median
Net margin (TTM)1% · Below median
Operating margin (TTM)9% · Above median
Growth and dividend
Revenue growth−5% · Below median
Dividend yield (TTM)2.1% · Above median
Balance sheet
Debt / equity0.16× · Above median
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
P/E (TTM)80.9× · Priciest 25%
P/B1.80× · Cheaper than median
P/S (TTM)1.16× · Cheaper than median
P/FCF1.0× · Cheapest 25%
EV/EBITDA11.9× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 27
PAST (return on equity)11· sector 9
HEALTH (low debt)92· sector 96
DIVIDEND (yield)41· sector 29
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Zhejiang DiAn Diagnostics Co Fair Value". https://www.fairvalue-calculator.com/stock/300244
Frequently asked questions
Is Zhejiang DiAn Diagnostics Co (300244) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of ¥12.74 versus a price of ¥16.99, about −25% upside (overvalued).
What is the fair value of 300244?
Our model-based fair value for Zhejiang DiAn Diagnostics Co is ¥12.74 (as of Sep 13, 2026), built from audited fundamentals. The current price: ¥16.99.
What is the quality score of 300244?
Zhejiang DiAn Diagnostics Co has a Quality Score of 61/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Zhejiang DiAn Diagnostics Co (300244)?
Our model-based price target is the fair value of ¥12.74 (as of Sep 13, 2026) from 24 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the Zhejiang DiAn Diagnostics Co stock forecast for 2026?
Our models put fair value at ¥12.74, about −25% upside versus a price of ¥16.99 (overvalued). The calculation is refreshed regularly with new filings.
What is the revenue of Zhejiang DiAn Diagnostics Co (300244)?
Zhejiang DiAn Diagnostics Co reported trailing-twelve-month revenue of about 10.0B CNY (latest available figure, as of Sep 13, 2026).
Does Zhejiang DiAn Diagnostics Co pay a dividend?
Zhejiang DiAn Diagnostics Co currently shows a dividend yield of about 2.06% relative to its recent price (as of Sep 13, 2026).
What growth is priced into Zhejiang DiAn Diagnostics Co (300244)?
For today's price to be fair in a discounted-cash-flow model, Zhejiang DiAn Diagnostics Co would have to grow free cash flow by -10.7 % per year for five years (discount rate 11.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -1.1 % per year. As of Sep 13, 2026.
What discount rate (WACC) does the fair value of 300244 use?
Our models discount Zhejiang DiAn Diagnostics Co at 11.0 %: a base by market capitalisation (small), damped by beta 0.71, country premium for China. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Zhejiang DiAn Diagnostics Co that is -10.7 % per year a year over ten years, using the same discount rate (11.0 %) and the same formula as our fair value.
How much growth has Zhejiang DiAn Diagnostics Co (300244) delivered so far?
Over the past 5 years revenue at Zhejiang DiAn Diagnostics Co grew -1.1 % a year. The price currently implies -10.7 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Zhejiang DiAn Diagnostics Co (300244) growing?
The median revenue growth in the sector is +4.3 % a year. That is the yardstick for the growth priced into Zhejiang DiAn Diagnostics Co (-10.7 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Zhejiang DiAn Diagnostics Co (300244)?
The free-cash-flow yield on the price is 16.42 %: that much free cash flow Zhejiang DiAn Diagnostics Co produces per unit of market value. When it exceeds the discount rate of our models (11.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Zhejiang DiAn Diagnostics Co (300244)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Zhejiang DiAn Diagnostics Co it is ¥12.74 per share (as of Sep 13, 2026), against a price of ¥16.99. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Zhejiang DiAn Diagnostics Co stock overvalued or undervalued in 2026?
As of Sep 13, 2026, 300244 trades above its calculated fair value: price ¥16.99, fair value ¥12.74, a gap of about −25% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 300244?
No. The price is what the market pays today (¥16.99); the fair value is what the company's own numbers justify (¥12.74). For Zhejiang DiAn Diagnostics Co the two are ¥4.25 per share apart. That gap is exactly why we show both numbers side by side.
How much is Zhejiang DiAn Diagnostics Co worth?
The market values Zhejiang DiAn Diagnostics Co at about 11.6B CNY (market capitalisation, as of Sep 13, 2026). Per share that is ¥16.99; our models calculate a fair value of ¥12.74 per share.
What is the P/E ratio of 300244?
Zhejiang DiAn Diagnostics Co trades at a price-to-earnings ratio of 80.9 (as of Sep 13, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥12.74 is built from several models across several years. Other multiples: P/B 1.8, P/S 1.2, EV/EBITDA 11.9.
How solid is the balance sheet of Zhejiang DiAn Diagnostics Co (300244)?
Balance-sheet figures for Zhejiang DiAn Diagnostics Co (as of Sep 13, 2026): return on equity 2.8%, debt of 0.16 per unit of equity. They feed the Quality Score of 61/100, which measures business quality independently of the share price.
How far is 300244 from its 52-week high?
Zhejiang DiAn Diagnostics Co trades at ¥16.99, about 49% below its 52-week high of ¥33.30 and 26% above the low of ¥13.52 (as of Sep 13, 2026). Distance from the high says nothing about value: that is what the fair value of ¥12.74 is for.
Which stocks are comparable to Zhejiang DiAn Diagnostics Co?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Zhejiang DiAn Diagnostics Co stock attractive at the current price?
The data as of Sep 13, 2026: price ¥16.99, calculated fair value ¥12.74 (−25%), Quality Score 61/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 300244 calculated?
We run Zhejiang DiAn Diagnostics Co through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥12.74, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.8 % above its aggregate fair value. Zhejiang DiAn Diagnostics Co itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What should I pay attention to with Zhejiang DiAn Diagnostics Co right now?
The price sits above even our optimistic bull case (¥12.74). The favourable scenario is already priced in. Solid but not exceptional quality (61/100) and above fair value, neither a clear bargain nor a standout compounder. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Where does the earnings growth of Zhejiang DiAn Diagnostics Co (300244) come from?
Earnings per share at Zhejiang DiAn Diagnostics Co grew +21.6 % a year from 2013 to 2024. Broken into its drivers: revenue per share +30.0 %, EBIT margin +0.1 %, tax rate −2.7 %, residual (interest, one-offs) −4.0 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Zhejiang DiAn Diagnostics Co
How large is the market capitalisation of Zhejiang DiAn Diagnostics Co (300244)?
The market capitalisation of Zhejiang DiAn Diagnostics Co is 11.6B CNY (≈ $1.7B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Zhejiang DiAn Diagnostics Co (300244)?
The price-to-sales ratio of Zhejiang DiAn Diagnostics Co is 0.35 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Zhejiang DiAn Diagnostics Co (300244)?
Earnings per share at Zhejiang DiAn Diagnostics Co are ¥0.2100 (price ÷ EPS = P/E 80.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Zhejiang DiAn Diagnostics Co (300244)?
The dividend yield of Zhejiang DiAn Diagnostics Co is 2.1% (payout 167%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Zhejiang DiAn Diagnostics Co (300244)?
The net margin of Zhejiang DiAn Diagnostics Co is 0.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Zhejiang DiAn Diagnostics Co (300244)?
The return on equity (ROE) of Zhejiang DiAn Diagnostics Co is 2.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Zhejiang DiAn Diagnostics Co (300244)?
On an EBIT basis the return on assets of Zhejiang DiAn Diagnostics Co is 7.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Zhejiang DiAn Diagnostics Co (300244)?
The operating margin of Zhejiang DiAn Diagnostics Co is 8.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Zhejiang DiAn Diagnostics Co (300244)?
Revenue at Zhejiang DiAn Diagnostics Co is growing −5.0% versus a year earlier (3y avg −20.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Zhejiang DiAn Diagnostics Co (300244)?
Earnings per share at Zhejiang DiAn Diagnostics Co are growing −21.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Zhejiang DiAn Diagnostics Co (300244) carry?
The net debt of Zhejiang DiAn Diagnostics Co is 571M CNY (fiscal year 2024, ≈ 0.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Zhejiang DiAn Diagnostics Co in the live analysis
One click puts Zhejiang DiAn Diagnostics Co on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
